AB
ALNY icon

Amalgamated Bank’s Alnylam Pharmaceuticals ALNY Stock Holding History

Amalgamated Bank’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.1M Buy
10,313
+376
+4% +$113K 0.02% 637
2026
Q1 		$3.29M Sell
9,937
-742
-7% -$252K 0.03% 591
2025
Q4 		$4.25M Buy
10,679
+535
+5% +$237K 0.03% 484
2025
Q3 		$4.63M Buy
10,144
+676
+7% +$275K 0.03% 451
2025
Q2 		$3.09M Buy
9,468
+615
+7% +$170K 0.02% 606
2025
Q1 		$2.39M Buy
8,853
+369
+4% +$94.8K 0.02% 701
2024
Q4 		$2M Buy
8,484
+205
+2% +$53.9K 0.02% 801
2024
Q3 		$2.28M Sell
8,279
-75
-0.9% -$19.5K 0.02% 760
2024
Q2 		$2.03M Buy
8,354
+301
+4% +$47.5K 0.02% 833
2024
Q1 		$1.2M Sell
8,053
-3,306
-29% -$551K 0.01% 996
2023
Q4 		$2.17M Sell
11,359
-1,387
-11% -$236K 0.02% 877
2023
Q3 		$2.26M Sell
12,746
-400
-3% -$76.3K 0.02% 831
2023
Q2 		$2.5M Sell
13,146
-932
-7% -$185K 0.02% 794
2023
Q1 		$2.82M Buy
14,078
+211
+2% +$44.4K 0.02% 732
2022
Q4 		$3.29M Buy
13,867
+387
+3% +$82.5K 0.03% 700
2022
Q3 		$2.7M Buy
13,480
+213
+2% +$40.6K 0.03% 698
2022
Q2 		$1.94M Sell
13,267
-88
-0.7% -$12.5K 0.02% 880
2022
Q1 		$2.18M Buy
13,355
+2,877
+27% +$438K 0.02% 888
2021
Q4 		$1.78M Buy
10,478
+3,602
+52% +$669K 0.01% 998
2021
Q3 		$1.3M Sell
6,876
-1,068
-13% -$200K 0.01% 1125
2021
Q2 		$1.35M Buy
7,944
+2,264
+40% +$332K 0.01% 1140
2021
Q1 		$802K Sell
5,680
-338
-6% -$50.9K 0.03% 704
2020
Q4 		$782K Sell
6,018
-88
-1% -$11.8K 0.03% 700
2020
Q3 		$889K Sell
6,106
-43
-0.7% -$6.11K 0.04% 506
2020
Q2 		$911K Sell
6,149
-20,994
-77% -$2.83M 0.04% 459
2020
Q1 		$2.96M Sell
27,143
-331
-1% -$38.2K 0.07% 241
2019
Q4 		$3.16M Buy
27,474
+1,506
+6% +$150K 0.06% 312
2019
Q3 		$2.09M Buy
25,968
+2,888
+13% +$228K 0.04% 420
2019
Q2 		$1.68M Buy
23,080
+2,109
+10% +$162K 0.04% 496
2019
Q1 		$1.96M Buy
20,971
+1,401
+7% +$117K 0.05% 393
2018
Q4 		$1.43M Buy
19,570
+6,795
+53% +$523K 0.04% 472
2018
Q3 		$1.12M Sell
12,775
-7,645
-37% -$769K 0.03% 626
2018
Q2 		$2.01M Buy
20,420
+2,080
+11% +$206K 0.05% 383
2018
Q1 		$2.18M Buy
18,340
+1,228
+7% +$158K 0.06% 335
2017
Q4 		$2.17M Buy
17,112
+2,070
+14% +$260K 0.06% 319
2017
Q3 		$1.77M Buy
15,042
+1,084
+8% +$92.5K 0.06% 346
2017
Q2 		$1.11M Buy
13,958
+3,052
+28% +$195K 0.04% 585
2017
Q1 		$559K Sell
10,906
-2,055
-16% -$95K 0.03% 769
2016
Q4 		$485K Buy
12,961
+1,392
+12% +$58.3K 0.02% 854
2016
Q3 		$784K Buy
11,569
+4
+0% +$282 0.05% 486
2016
Q2 		$859K Buy
+11,565
New +$729K 0.05% 443
2015
Q3 		– Sell
-2,224
Closed -$267K – 1311
2015
Q2 		$267K Sell
2,224
-4,968
-69% -$594K 0.03% 1057
2015
Q1 		$751K Buy
7,192
+818
+13% +$82.9K 0.09% 265
2014
Q4 		$618K Buy
6,374
+17
+0.3% +$1.57K 0.1% 262
2014
Q3 		$496K Buy
6,357
+79
+1% +$5.1K 0.07% 350
2014
Q2 		$397K Buy
6,278
+601
+11% +$35.7K 0.06% 461
2014
Q1 		$381K Sell
5,677
-51
-0.9% -$3.95K 0.07% 438
2013
Q4 		$368K Buy
+5,728
New +$342K 0.06% 459

Other funds holding ALNY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Amalgamated Bank's ALNY Position: Q2 2026 in Review

Amalgamated Bank increased its Alnylam Pharmaceuticals (ALNY) stake by 3.8% in Q2 2026, buying an estimated $113K and bringing the position to 10,313 shares worth $3.1M. The position accounts for 0.02% of the portfolio, ranked #637.

Amalgamated Bank first reported a position in ALNY in Q4 2013 and has held it in 48 quarters since. The position peaked at $4.63M in Q3 2025. 365 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Amalgamated Bank held 10,313 shares of Alnylam Pharmaceuticals worth $3.1M as of Q2 2026.
  • Amalgamated Bank bought 376 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $113K.
  • Alnylam Pharmaceuticals made up 0.02% of Amalgamated Bank's portfolio in Q2 2026, its #637 holding.
  • Amalgamated Bank first reported a position in Alnylam Pharmaceuticals in Q4 2013 and has held it in 48 quarters since.
  • Amalgamated Bank's Alnylam Pharmaceuticals position peaked at $4.63M in Q3 2025.
  • 365 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Amalgamated Bank's 13F filing for Q2 2026, filed 23 Jul 2026.